Literature DB >> 87736

Significance of elevated mid-trimester maternal plasma-alpha-fetoprotein values.

D J Brock, L Barron, P Duncan, J B Scrimgeour, M Watt.   

Abstract

In a prospective trial of 15,481 pregnancies, 667 women (4.3%) had two sequential mid-trimester plasma-alpha-fetoprotein (A.F.P.) values above 2 times the median. The outcome of these pregnancies was open neural-tube defect (12.4%), birthweight less than 2.5 kg (10.3%), twins (9.8%), fetal wastage (9.5%), perinatal death (2.6%), other (1.3%), and "normal" singleton (54.1%). At higher A.F.P. cutoffs the proportion of "normal" singleton pregnancies declined rapidly, being 19% at 3 times the median and 9% at 4 times the median. If it is assumed that ultrasonography and amniotic-fluid A.F.P. assay can detect twins and most cases of neural-tube defect, the outcome of the residual pregnancies is still strongly influenced by plasma-A.F.P. level. Thus at a cut-off of 4 times the median two-thirds of the pregnancies in this residual group will end in spontaneous abortion, stillbirth, or neonatal death. It is suggested that counselling of women taking part in A.F.P. screening programmes should be strongly influenced by maternal plasma-A.F.P. levels, even if ultrasonographic findings and amniotic-fluid levels are normal.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 87736     DOI: 10.1016/s0140-6736(79)92238-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects.

Authors:  W Fuhrmann; H K Weitzel
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

2.  Maternal serum alpha-fetoprotein screening: report of a Canadian pilot project.

Authors:  T A Doran; G H Valentine; P Y Wong; G Wielgosz; R J Benzie; H C Soltan; M R Jenner; P A Morland; R J Montgomery; L C Allen
Journal:  CMAJ       Date:  1987-08-15       Impact factor: 8.262

3.  Stress after amniocentesis for high serum alpha-fetoprotein concentrations.

Authors:  R Harris; A P Read; D Donnai; P Donnai
Journal:  Br Med J       Date:  1980-09-20

Review 4.  Maternal serum alphafetoprotein in pregnancy and the prevention of birth defect.

Authors:  R Harris
Journal:  Br Med J       Date:  1980-05-17

5.  Prenatal fetal karyotyping and maternal serum alpha-fetoprotein screening.

Authors:  C Gosden; K Buckton; Z Fotheringham; D J Brock
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-24

6.  Alpha-fetoprotein: a biochemical marker of fetal well-being.

Authors:  A Gupta; I C Verma; P S Menon
Journal:  Indian J Pediatr       Date:  1983 Mar-Apr       Impact factor: 1.967

7.  Maternal serum alpha-fetoprotein for prediction of fetal and neonatal morbidity and mortality.

Authors:  A Gupta; I C Verma; P S Menon
Journal:  Indian J Pediatr       Date:  1982 May-Jun       Impact factor: 1.967

8.  Impact of maternal serum alpha-fetoprotein screening on antenatal diagnosis.

Authors:  D J Brock
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-31

9.  Maternal alpha-fetoprotein screening: two years' experience in a low-risk district.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-07

10.  Cytomegalovirus infection in association with early onset pre-eclampsia.

Authors:  L Higgins; S Vause; C Tower
Journal:  BMJ Case Rep       Date:  2010-11-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.